The Future of MRD-Guided Therapy in GU Oncology

In this closing segment, panelists reflect on the evolving role of molecular residual disease (MRD) testing and ctDNA in shaping the future of GU oncology. They highlight recent data demonstrating the prognostic and predictive value of ctDNA, particularly in guiding adjuvant therapy decisions in bladder cancer. The discussion emphasizes the potential for ctDNA to refine risk stratification, reduce overtreatment, and enable more personalized care. At the same time, challenges remain, including assay limitations, variability across tumor types, and the need for standardized clinical pathways. Panelists express optimism that ongoing research and clinical trials will further define the role of ctDNA in routine practice. This segment concludes with a forward-looking perspective on how molecular monitoring will continue to transform cancer care.